Adenocarcinoma of the lung other diagnostic studies: Difference between revisions

	Adenocarcinoma of the Lung Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adenocarcinoma of the Lung from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Intervention
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Adenocarcinoma of the lung other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adenocarcinoma of the lung other diagnostic studies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adenocarcinoma of the lung other diagnostic studies
CDC on Adenocarcinoma of the lung other diagnostic studies
Adenocarcinoma of the lung other diagnostic studies in the news
Blogs on Adenocarcinoma of the lung other diagnostic studies
Directions to Hospitals Treating Adenocarcinoma of the lung
Risk calculators and risk factors for Adenocarcinoma of the lung other diagnostic studies

Revision as of 15:04, 5 January 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]

Molecular Test^[1]

Molecular tissue tests look for certain changes in the genes of non–small cell lung cancer cells. These genetic mutations may change how much or the type of protein the cancer cells produce. These changes may affect the type of treatment given because some chemotherapy drugs may be more effective against cancer cells with these changes. Molecular tissue tests may also help predict prognosis.

Molecular tissue tests for non-small cell lung cancer look for the genes responsible for:

Specific mutations in these genes are associated with a better response to some drugs.

@@ Line 4: / Line 4: @@
 ==Overview==
-==Molecular Test==
+==Other Diagnostic Studies==
-Molecular tests include epidermal growth factor receptor ([[EGFR]]) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present.
+'''Molecular Test'''<ref>Lung cancer. Canadian Cancer Society 2015.http://www.cancer.ca/en/cancer-information/cancer-type/lung/diagnosis/?region=ab#Endoscopy</ref>
+* Molecular tissue tests look for certain changes in the genes of non–small cell lung cancer cells. These genetic mutations may change how much or the type of protein the cancer cells produce. These changes may affect the type of treatment given because some [[chemotherapy]] drugs may be more effective against cancer cells with these changes. Molecular tissue tests may also help predict [[prognosis]].
+* Molecular tissue tests for non-small cell lung cancer look for the genes responsible for:
+:* [[Epidermal growth factor receptor]] (EGFR)
+:* [[Anaplastic lymphoma fusion]] (ALK)
+* Specific mutations in these genes are associated with a better response to some drugs.
 ==References==